Evotec extends Huntington's collaboration
This article was originally published in Scrip
Executive Summary
Evotec has extended its collaboration with CHDI Foundation through to the end of 2012. The collaboration, which is aimed at finding new treatments for Huntington's disease, will provide Evotec with up to $37.5 million in research funding over the next three years. Evotec has been providing research and innovation support to CHDI since 2006.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.